AbbVie secures another Humira settlement

AbbVie has announced yet another settlement relating to litigation over Humira (adalimumab), a drug used to treat multiple types of arthritis as well as psoriasis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Adamas settles Gocovri clash with Sandoz

3 January 2020 California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie escalates Humira battle with Sandoz

13 August 2018 AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.

More on this story

Americas

Adamas settles Gocovri clash with Sandoz

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie escalates Humira battle with Sandoz

13 August 2018 AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.

More on this story

Americas

Adamas settles Gocovri clash with Sandoz

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie escalates Humira battle with Sandoz

13 August 2018 AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair.